Daily use of parathyroid hormone hPTH (1-34) treatment among postmenopausal women with glucocorticoid-induced osteoporosis may be associated with an increase in vertebral bone strength, coupled with a reduction in risks of fracture.
This is the cautious speculation, as they put it, by clinicians at the Departments of Medicine and Radiology, University of California at San Francisco. Their study arose from the fact that daily hPTH (1-34) is associated with a significant increase in bone formation, which results in large gains in lumbar spine bone mass on trabecular, endocortical and periosteal surfaces.
This prompted the clinicians to see if daily treatment with hPTH (1-34) over one year could produce a change in vertebral cross-sectional area, or vertebral size. These changes would be assessed by serial quantitative computed tomography (QCT) scans.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!